Loading
Life sciences · Journal article
Exploration of Neuroscience · September 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Targeted cancer therapies for cancer treatment are at the forefront of cancer treatments. The identification of pathologic cell signaling pathways in cancer cells via precision medicine enables the development of new therapies to target the underpinning molecular changes within tumor cells. Applying these techniques to brain tumors is no different, except for the added necessity that these therapeutics penetrate the blood-brain barrier. Besides cell signaling alterations seen in other cancers outside of the brain (such as receptor tyrosine kinase pathways, Raf/MEK/Erk pathway, PI3K/AKT/mTOR pathway, to name a few), there are several cell-signaling pathway aberrations unique to central nervous system tumors (for example isocitrate dehydrogenase mutations or O6-methylguanine DNA methyltransferase methylation status) that allow for therapies to specifically target brain tumors. Herein, we describe the various molecular pathway aberrations that have been identified and used to develop targeted molecular therapies for brain tumors.